ATS Stat

HomeATS Stat ▶ Stat April 5, 2017
Stat April 5, 2017

Register by April 10 for ATS Hill Day in DC

ATS 2017 takes advantage of its Washington, DC, location with a special Capitol Hill Day for U.S. attendees. Interested in lung health advocacy and meeting your Congressional Delegation while at the conference? Learn more and register today.

U.S. ATS members only. Advanced registration required. Deadline: April 10.

Hill Day From a Fellow’s Perspective

Shubha V. Srinivas, MD, MPH, was one of two fellows selected to receive the 2017 Hill Day Fellowship, which supported her to attend the Annual ATS Hill Day on March 29. “Advocating on Capitol Hill is easier than one would think. There wasn’t anything intimidating about the experience, and the legislative staffers were open-minded and curious to hear from physicians who were new to the advocacy process.” She adds that physicians have a voice and privilege to advocate for improving patient care. As a result of her participation in the March Hill Day, Dr. Srinivas was motivated and inspired by the camaraderie of her advocacy team. Like the other fellows present, she was taken under the mentorship of ATS members with more seasoned health policy experience. “Hill Day is a great networking experience in the lung disease community; I highly recommend participating in the Hill Session at the International Conference.”

April Journal Clubs

Tune in to these Journal Clubs, presented by the following ATS Assemblies:

  • Assembly on Pediatrics at 1 p.m. ET, April 7:
    “Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR”
    To reserve your Webinar seat today click here.
  • Assembly on Allergy, Immunology at 11 a.m. ET, April 12:
    “Beta-Glucan Reverses the Epigenetic State of LPS-Induced Immunological Tolerance”
    To reserve your Webinar seat today click here.
  • Assembly on Pulmonary Circulation at 11 a.m. ET, April 13 for a debate on catheter-based thrombolysis in acute pulmonary embolism.
    To reserve your Webinar seat today click here.
  • Section of Medical Education at 2 p.m. ET, April 14:
    “2017 Update: Preparing Effective Poster and Slide Presentations for National Meetings”
    To reserve your Webinar seat today click here.

Join Us for the 3rd Annual BEAR Cage

The ATS Drug Device Discovery and Development (DDDD) Committee is excited to announce the three finalists for the 3rd Annual BEAR Cage (Building Education to Advance Research) competition, to be held at the Center for Career Development at ATS 2017. Early career professionals were asked to submit their innovative clinical or translational research proposals in the beginning of the year for the opportunity to “pitch” their projects to a panel of translational science experts during the 2017 BEAR Cage. Please join us for the live event from 2‒4 p.m., Sunday, May 21, to cheer on the finalists: Marcus Y. Chen, MD (Chest CT at Chest X-ray Radiation Dose); Prema R. Menon, MD, PhD (Communicating with Mechanically Ventilated Patients); and Sanghyuk Shin, PhD (Unmasking Resistance: Impact of Low-frequency Drug Resistance on Molecular Diagnosis of Drug-Resistant Tuberculosis). The grand prize for the competition will be $5,000. View the program details and presenters.

ATS Clinical Trial Resources

Check out the ATS Clinical Trial Resources page to find the latest about current and ongoing clinical trials in pulmonary, critical care, and sleep medicine, conducted by participating pharmaceutical and device companies. For example, you can learn about the recently updated INHALE 1 and 2 trials in pneumonia, run by Bayer HealthCare AG/Nektar to evaluate the safety and efficacy of amikacin ianhale as adjunctive therapy in intubated and mechanically-ventilated patients with gram-negative pneumonia, as well as additional ongoing trials in Asthma, COPD, IPF, ILD, and Lung Infection.

Email us to join the listserve to receive updates and new clinical trial information.

EpiPen Recall

Mylan Provides Update on Meridian Medical Technologies’, a Pfizer Company, Expanded Voluntary Worldwide Recall of EpiPen® Auto-Injector HERTFORDSHIRE, England and PITTSBURGH, PA – March 31, 2017 – Mylan N.V. (NASDAQ, TASE:MYL) announced that Meridian Medical Technologies, a Pfizer company and Mylan’s manufacturing partner for EpiPen® Auto-Injector, has expanded a voluntary recall of select lots of EpiPen (epinephrine injection, USP) and EpiPen Jr® (epinephrine injection, USP) Auto-Injectors to now include additional lots distributed in the U.S. and other markets in consultation with the U.S. Food and Drug Administration (FDA). Patients, customers and distributors are being notified and should refer to for updates on product return and replacement instructions.

Last Reviewed: October 2017